SHP2-IN-46 

SHP2-IN-46 is an orally active SHP2 inhibitor (IC₅₀ = 11.76 μM). SHP2-IN-46 inhibits SHP2 enzymatic activity and mediates anti-tumor activity. SHP2-IN-46 suppresses cell proliferation in various cancer cells. SHP2-IN-46 can be used in research related to lung adenocarcinoma, pancreatic cancer and hepatoblastoma^[1].

SHP2-IN-46 (72 h) potently inhibits the proliferation of A549, MIA PaCa-2, and HepG2 cancer cells with IC₅₀ values of 0.24 μM, 0.16 μM, and 0.09 μM, respectively^[1].
SHP2-IN-46 (24 h) induces S-phase cell cycle arrest in HepG2 cells, disrupting cell proliferation^[1].
SHP2-IN-46 (up to 60 min) shows favorable metabolic stability in human liver microsomes, with an in vitro T_1/2 of 40.63 min and CL_int of 34.11 μL/min/mg protein^[1].
SHP2-IN-46 (0.001-100 μM; 60 min enzyme incubation; 30 min substrate incubation) inhibits SHP2 enzyme activity with an IC₅₀ value of 11.76 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

SHP2-IN-46 (50-200 mg/kg; p.o.; single dose) has a maximum tolerated dose greater than 200 mg/kg in ICR mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

309.37

C₁₇H₁₉N₅O

3086360-36-0

CC(C=C1NC2=CC=CC=C2C)=NN1C(N3)=NC(C)=C(C)C3=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Kou S, et al. Design, synthesis, and antiproliferative evaluation of dihydropyrimidinone-pyrazole derivatives as potential SHP2 inhibitors via in silico target prediction. Future Med Chem. 2026;18(1):49-66.  [Content Brief]